Skin Diseases, Vascular
Welcome,         Profile    Billing    Logout  
 40 Companies   36 Products   36 Products   38 Mechanisms of Action   0 Trials   262 News 


123456»
  • ||||||||||  dobutamine / Generic mfg.
    Trial completion, Phase classification, Enrollment change, Trial completion date, Trial primary completion date, MRI:  ECHOBIKE: Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging (clinicaltrials.gov) -  Mar 14, 2019   
    P=N/A,  N=124, Completed, 
    Enrolling by invitation --> Completed | Phase classification: P1 --> PN/A | N=80 --> 124 | Trial completion date: Jun 2011 --> Mar 2019 | Trial primary completion date: Jun 2010 --> Feb 2019
  • ||||||||||  Enrollment change, Trial completion date, Trial termination:  DTCU: Dietary Treatment for Chronic Urticaria (clinicaltrials.gov) -  Aug 2, 2018   
    P=N/A,  N=8, Terminated, 
    Recruiting --> Completed N=78 --> 8 | Trial completion date: Dec 2017 --> Jul 2018 | Recruiting --> Terminated; Unable to recruit subjects, patients want active treatment instead of placebo.
  • ||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
    Trial completion:  Cold Contact Urticaria Treatment With Rilonacept (clinicaltrials.gov) -  Jul 17, 2018   
    P2,  N=20, Completed, 
    N=78 --> 8 | Trial completion date: Dec 2017 --> Jul 2018 | Recruiting --> Terminated; Unable to recruit subjects, patients want active treatment instead of placebo. Active, not recruiting --> Completed
  • ||||||||||  Ruconest (conestat alfa) / SOBI, Pharming Group
    Trial completion, Trial completion date, Trial primary completion date:  Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients (clinicaltrials.gov) -  Jul 13, 2018   
    P2,  N=20, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Dec 2017 --> Jul 2017 | Trial primary completion date: Dec 2017 --> Jul 2017
  • ||||||||||  Enrollment change:  Response of Urticaria to Stress Intervention (clinicaltrials.gov) -  Feb 20, 2018   
    P=N/A,  N=0, Withdrawn, 
    N=46 --> 126 N=30 --> 0
  • ||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
    Enrollment closed:  Cold Contact Urticaria Treatment With Rilonacept (clinicaltrials.gov) -  Dec 15, 2017   
    P2,  N=20, Active, not recruiting, 
    N=30 --> 0 Recruiting --> Active, not recruiting
  • ||||||||||  Xolair (omalizumab) / Roche, Novartis
    Trial completion:  Efficacy and Safety Study of Omalizumab (Xolair (clinicaltrials.gov) -  Oct 24, 2017   
    P2,  N=20, Completed, 
    Recruiting --> Completed | Trial primary completion date: May 2015 --> Jun 2016 Enrolling by invitation --> Completed
  • ||||||||||  Xolair (omalizumab) / Roche, Novartis
    Trial completion:  CUN-OMAL-UCOL: Efficacy Study of Omalizumab in Cholinergic Urticaria (clinicaltrials.gov) -  Oct 24, 2017   
    P2,  N=24, Completed, 
    Enrolling by invitation --> Completed Active, not recruiting --> Completed
  • ||||||||||  Enrollment change, Trial primary completion date:  Methotrexate in the Treatment of Chronic Idiopathic Urticaria (clinicaltrials.gov) -  Sep 20, 2017   
    P3,  N=83, Completed, 
    Initiation date: Dec 2014 --> Dec 2015 N=110 --> 83 | Trial primary completion date: Nov 2013 --> Mar 2016
  • ||||||||||  Trial completion, Trial primary completion date:  Protocol For The Quantitation Of Pain In The Diagnosis Of Polymyalgia Rheumatica (clinicaltrials.gov) -  Aug 23, 2017   
    P=N/A,  N=142, Completed, 
    N=110 --> 83 | Trial primary completion date: Nov 2013 --> Mar 2016 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Aug 2013
  • ||||||||||  dobutamine / Generic mfg.
    Trial completion, Enrollment change, Trial primary completion date:  Prevalence and Early Markers of Atherosclerosis in Adults With a History of Kawasaki Disease (clinicaltrials.gov) -  Aug 22, 2017   
    P=N/A,  N=43, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Aug 2013 Recruiting --> Completed | N=100 --> 43 | Trial primary completion date: Mar 2016 --> Apr 2015
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Trial completion, Trial initiation date, IO biomarker:  Study of Tocilizumab to Treat Polymyalgia Rheumatica (clinicaltrials.gov) -  Mar 15, 2017   
    P2a,  N=10, Completed, 
    Active, not recruiting --> Completed | N=250 --> 473 Active, not recruiting --> Completed | Initiation date: Jul 2011 --> Apr 2011
  • ||||||||||  Trial completion, Enrollment change:  UCT-V: Validation of an Urticaria Control Test (clinicaltrials.gov) -  Jan 6, 2017   
    P=N/A,  N=120, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Completed | N=100 --> 120
  • ||||||||||  Trial completion, Enrollment change:  UCT-D: Development of an Urticaria Control Test (clinicaltrials.gov) -  Jan 6, 2017   
    P=N/A,  N=508, Completed, 
    Recruiting --> Completed | N=100 --> 120 Recruiting --> Completed | N=300 --> 508
  • ||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
    Trial primary completion date:  Cold Contact Urticaria Treatment With Rilonacept (clinicaltrials.gov) -  Jan 6, 2017   
    P2,  N=20, Recruiting, 
    Recruiting --> Completed | N=300 --> 508 Trial primary completion date: Feb 2017 --> Dec 2017
  • ||||||||||  Trial completion, Trial primary completion date:  SOS AOH: A Call Center During HAE Attacks (SOS HAE) (clinicaltrials.gov) -  Dec 13, 2016   
    P4,  N=200, Completed, 
    Trial primary completion date: Feb 2017 --> Dec 2017 Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Sep 2016
  • ||||||||||  Humira (adalimumab) / AbbVie
    Trial completion, Enrollment change:  Efficacy of Humira in Behcet Patients With Arthritis (clinicaltrials.gov) -  Oct 26, 2016   
    P3,  N=9, Completed, 
    Recruiting --> Active, not recruiting Recruiting --> Completed | N=15 --> 9
  • ||||||||||  Ruconest (conestat alfa) / SOBI, Pharming Group
    Trial completion, P2 data:  A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor (clinicaltrials.gov) -  Oct 17, 2016   
    P2,  N=32, Completed, 
    Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed
  • ||||||||||  Ilaris (canakinumab) / Novartis
    Trial completion, Enrollment change, Trial primary completion date:  Canakinumab for Pyoderma Gangrenosum (clinicaltrials.gov) -  Sep 27, 2016   
    P2,  N=5, Completed, 
    Trial primary completion date: Sep 2016 --> Dec 2016 Recruiting --> Completed | N=10 --> 5 | Trial primary completion date: Aug 2012 --> Aug 2014
  • ||||||||||  bilastine / Generic mfg.
    Trial completion, Trial primary completion date:  Bilastine Updosing in Chronic Spontaneous Urticaria (clinicaltrials.gov) -  Aug 26, 2016   
    P3,  N=30, Completed, 
    Trial primary completion date: Sep 2016 --> Dec 2016 Recruiting --> Completed | Trial primary completion date: Jun 2016 --> Mar 2016
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Study of the Effects of Chinese Herbal Medicine on Chronic Urticaria (clinicaltrials.gov) -  Jun 5, 2016   
    P3,  N=74, Completed, 
    Recruiting --> Active, not recruiting Recruiting --> Completed | N=100 --> 74 | Trial primary completion date: Dec 2015 --> Aug 2015
  • ||||||||||  pravastatin / Generic mfg.
    Biomarker, Enrollment change:  Cardiovascular Risk Markers and Response to Statins After Kawasaki Disease (clinicaltrials.gov) -  May 25, 2016   
    P2,  N=0, Withdrawn, 
    Recruiting --> Completed | N=100 --> 74 | Trial primary completion date: Dec 2015 --> Aug 2015 N=22 --> 0
  • ||||||||||  gevokizumab (S 78989) / Novartis
    Enrollment change, Trial termination, Trial primary completion date:  A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum (clinicaltrials.gov) -  Apr 27, 2016   
    P3,  N=15, Terminated, 
    N=58 --> 9 | Recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Mar 2016 N=100 --> 15 | Enrolling by invitation --> Terminated | Trial primary completion date: Oct 2018 --> Feb 2016
  • ||||||||||  gevokizumab (S 78989) / Novartis
    Enrollment change, Trial termination, Trial primary completion date:  An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum (clinicaltrials.gov) -  Apr 27, 2016   
    P3,  N=16, Terminated, 
    N=100 --> 15 | Enrolling by invitation --> Terminated | Trial primary completion date: Oct 2018 --> Feb 2016 N=58 --> 16 | Recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Mar 2016
  • ||||||||||  Firazyr (icatibant) / Takeda
    Trial primary completion date:  Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema (clinicaltrials.gov) -  Apr 7, 2016   
    P0,  N=21, Terminated, 
    N=58 --> 16 | Recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Mar 2016 Trial primary completion date: May 2015 --> Sep 2015